Vital signs: Prescription opioid pain reliever use during pregnancy - 34 U.S. Jurisdictions, 2019

Morbidity and Mortality Weekly Report

Volumn 69, Issue 28, 2020, Pages 897-903

  Ko, Jean Y ^a   D'Angelo, Denise V ^a   Haight, Sarah C ^a   Morrow, Brian ^a   Cox, Shanna ^a   von Essen, Beatriz Salvesen ^a   Strahan, Andrea E ^b   Harrison, Leslie ^a   Tevendale, Heather D ^a   Warner, Lee ^a   Kroelinger, Charlan D ^a   Barfield, Wanda D ^a  

^a NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

^b NATIONAL CENTER FOR INJURY PREVENTION AND CONTROL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NARCOTIC ANALGESIC AGENT; PRESCRIPTION DRUG;

ADOLESCENT; ADULT; CHRONIC PAIN; EPIDEMIOLOGY; FEMALE; HEALTH CARE SURVEY; HUMAN; PATIENT EDUCATION; PREGNANCY; PRENATAL EXPOSURE; PRESCRIPTION DRUG MISUSE; RISK ASSESSMENT; SELF REPORT; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; ANALGESICS, OPIOID; CHRONIC PAIN; FEMALE; HEALTH CARE SURVEYS; HUMANS; PATIENT EDUCATION AS TOPIC; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PRESCRIPTION DRUG MISUSE; PRESCRIPTION DRUGS; RISK ASSESSMENT; SELF REPORT; UNITED STATES; YOUNG ADULT;

EID: 85088273697     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: 10.15585/mmwr.mm6928a1     Document Type: Article

References (20)

1. Wilson N, Kariisa M, Seth P, Smith H IV, Davis NL. Drug and opioid-involved overdose deaths-United States, 2017-2018. MMWR Morb Mortal Wkly Rep 2020;69:290-7. https://doi.org/10.15585/mmwr. mm6911a4
2. Han B, Compton WM, Blanco C, Crane E, Lee J, Jones CM. Prescription opioid use, misuse, and use disorders in U.S. adults: 2015 National Survey on Drug Use and Health. Ann Intern Med 2017;167:293-301. https://doi.org/10.7326/M17-0865
3. Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain-United States, 2016. JAMA 2016;315:1624-45. https://doi.org/10.1001/jama.2016.1464
4. Schiff DM, Nielsen T, Terplan M, et al. Fatal and nonfatal overdose among pregnant and postpartum women in Massachusetts. Obstet Gynecol 2018;132:466-74. https://doi.org/10.1097/AOG.0000000000002734
5. Bateman BT, Hernandez-Diaz S, Rathmell JP, et al. Patterns of opioid utilization in pregnancy in a large cohort of commercial insurance beneficiaries in the United States. Anesthesiology 2014;120:1216-24. https://doi.org/10.1097/ALN.0000000000000172
6. Desai RJ, Hernandez-Diaz S, Bateman BT, Huybrechts KF. Increase in prescription opioid use during pregnancy among Medicaid-enrolled women. Obstet Gynecol 2014;123:997-1002. https://doi.org/10.1097/AOG.0000000000000208
7. Patrick SW, Dudley J, Martin PR, et al. Prescription opioid epidemic and infant outcomes. Pediatrics 2015;135:842-50. https://doi.org/10.1542/peds.2014-3299
8. Whiteman VE, Salemi JL, Mogos MF, Cain MA, Aliyu MH, Salihu HM. Maternal opioid drug use during pregnancy and its impact on perinatal morbidity, mortality, and the costs of medical care in the United States. J Pregnancy 2014;2014:906723. https://doi.org/10.1155/2014/906723
9. Shulman HB, D'Angelo DV, Harrison L, Smith RA, Warner L. The Pregnancy Risk Assessment Monitoring System (PRAMS): overview of design and methodology. Am J Public Health 2018;108:1305-13. https://doi.org/10.2105/AJPH.2018.304563
10. Committee on Obstetric Practice. Committee opinion no. 711: opioid use and opioid use disorder in pregnancy. Obstet Gynecol 2017;130:e81-94. https://doi.org/10.1097/AOG.0000000000002235
11. US Preventive Services Task Force. Screening for unhealthy drug use: US Preventive Services Task Force recommendation statement. JAMA 2020;323:2301-9. https://doi.org/10.1001/jama.2020.8020
12. Kozhimannil KB, Graves AJ, Levy R, Patrick SW. Nonmedical use of prescription opioids among pregnant U.S. women. Womens Health Issues 2017;27:308-15. https://doi.org/10.1016/j.whi.2017.03.001
13. Substance Abuse and Mental Health Services Administration. Clinical guidance for treating pregnant and parenting women with opioid use disorder and their infants. Rockville, MD: US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration; 2018. https://store.samhsa.gov/product/Clinical-Guidance-for-Treating-Pregnant-and-Parenting-Women-With-Opioid-Use-Disorder-and-Their-Infants/SMA18-5054
14. CDC. Prescription drug monitoring programs (PDMPs): what states need to know. Atlanta, GA: US Department of Health and Human Services, CDC; 2017. https://www.cdc.gov/drugoverdose/pdmp/states.html
15. CDC. Interactive Training Series for healthcare providers: applying CDC's guideline for prescribing opioids. Atlanta, GA: US Department of Health and Human Services, CDC; 2019. https://www.cdc.gov/drugoverdose/training/online-training.html
16. Kroelinger CD, Rice ME, Cox S, et al. State strategies to address opioid use disorder among pregnant and postpartum women and infants prenatally exposed to substances, including infants with neonatal abstinence syndrome. MMWR Morb Mortal Wkly Rep 2019;68:777-83. https://doi.org/10.15585/mmwr.mm6836a1
17. CDC. Perinatal quality collaboratives. Atlanta, GA: US Department of Health and Human Services, CDC; 2020. https://www.cdc.gov/reproductivehealth/maternalinfanthealth/pqc.htm
18. CDC. Rx awareness. Atlanta, GA: US Department of Health and Human Services, CDC; 2019. https://www.cdc.gov/rxawareness/index.html
19. Krans EE, Campopiano M, Cleveland LM, et al. National partnership for maternal safety: consensus bundle on obstetric care for women with opioid use disorder. Obstet Gynecol 2019;134:365-75. https://doi.org/10.1097/AOG.0000000000003381
20. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.